At T0, GLP-1 and PYY levels appear to be quantitatively reduced in patients with NAFLD, whereas SeP and aHSGF appear to be increased, according to the actual evidence (D’Alessio, 2016; Petta et al., 2016; Bifari et al., 2018). This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.